In recent years, practicing hepatologists have directed their attention to the most relevant
outcome of most chronic liver diseases (CLD), ie, the progressive substitution of the
functioning hepatic parenchyma with fibrotic tissue. Significant advancements in the
knowledge of cellular and molecular mechanisms of hepatic fibrogenesis have greatly
contributed to this change, and, currently, major efforts are directed at translating these
acquisitions in diagnostic and therapeutic applications. This article outlines differences …